U.S. C-Reactive Protein Testing Market 2024-2032 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Key Insights

The U.S. C-Reactive Protein Testing Market size was valued at USD 691.6 USD Million in 2023 and is projected to reach USD 979.66 USD Million by 2032, exhibiting a CAGR of 5.1 % during the forecast period. CRP testing is a form of cardiac analysis that provides information on the condition of the heart by quantifying the amount of CRP protein in the blood. It encompasses two types: CRP for prediction of cardiovascular disease and for acute-phase reactant. Some of its key characteristics are rapid feedback and affordability. Uses include assessing heart disease risk, and watching infections, and autoimmune diseases. The demand for hs-CRP testing in the US market is increasing because of its usefulness for determining the future risk of cardiovascular disease which is harmonized with the trend toward increased awareness of preventive care. Still, CRP testing within a standard range is essential for evaluating infectious and inflammatory diseases.

U.S. C-Reactive Protein Testing Trends

• Increasing adoption of C-reactive protein testing in hospitals and clinics
• Growing preference for point-of-care testing devices
• Development of new and innovative C-reactive protein testing technologies
• Emergence of online platforms for C-reactive protein testing

Driving Forces: What's Propelling the U.S. C-Reactive Protein Testing Market

• Rising healthcare expenditure in the U.S.
• Increasing demand for personalized medicine
• Growing healthcare awareness and improved diagnostic capabilities
• Innovations in C-reactive protein testing technologies
• Government and regulatory support for C-reactive protein testing

Challenges and Restraints in U.S. C-Reactive Protein Testing Market

• High cost of C-reactive protein testing
• Lack of awareness about C-reactive protein testing
• False positive and false negative test results
• Limited reimbursement for C-reactive protein testing
• Competition from other diagnostic tests

Emerging Trends in U.S. C-Reactive Protein Testing

• Development of C-reactive protein tests with improved sensitivity and specificity
• Growing adoption of telemedicine for C-reactive protein testing
• Use of artificial intelligence and machine learning in C-reactive protein testing
• Development of personalized C-reactive protein testing panels

Growth Catalysts in the U.S. C-Reactive Protein Testing Industry

• Increasing government initiatives to promote C-reactive protein testing
• Rising demand for C-reactive protein testing in emergency care
• Expanding applications of C-reactive protein testing in personalized medicine
• Growing adoption of C-reactive protein testing in research and development

Market Segmentation: U.S. C-Reactive Protein Testing Analysis

Product:

• Reagent & Kits
• Instruments

Assay Type:

• Chemiluminescence Immunoassay (CLIA)
• Immunoturbidimetry
• Nephelometry

Detection Range:

• Conventional CRP
• Hs-CRP

Setting:

• Laboratory Testing
• Point-of-Care (POC)

End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Leading Players in the U.S. C-Reactive Protein Testing Market

• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Siemens Healthcare Private Limited (Germany)
• Quest Diagnostics Incorporated (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Laboratory Corporation of America Holdings (U.S.)
• Abaxis (U.S.)
• Creative Diagnostics (U.S.)

Significant Developments in U.S. C-Reactive Protein Testing Sector

• December 2022 – The U.S. FDA granted 510(k) clearance for Siemens Healthcare Diagnostics Products GmbH’s CardioPhase hsCRP prognostic test.
• April 2022: The U.S. FDA approved ProciseDx’s ProciseDx instrument and C reactive protein test.

Comprehensive Coverage U.S. C-Reactive Protein Testing Market Report

• Market overview and trends
• Drivers and restraints
• Market segmentation
• Competitive landscape
• Growth catalysts
• Industry developments
• Key market players

Pricing Analysis

The pricing of C-reactive protein testing varies depending on the following factors:

• Type of test
• Setting
• End-user
• Insurance coverage

Import And Export Analysis

The U.S. is a net importer of C-reactive protein testing kits and reagents. The major import partners include China, Germany, and Switzerland.

Segmentation

• Product Type: C-reactive protein test kits and reagents
• Test Type: Chemiluminescence immunoassay (CLIA), immunoturbidimetry, nephelometry
• End User: Hospitals, clinics, diagnostic laboratories
• Geography: U.S.

Patent/Trademark Analysis

Several patents and trademarks have been filed in the U.S. for C-reactive protein testing technologies. These include:

• U.S. Patent No. 9,229,006: C-reactive protein assay kit
• U.S. Patent No. 8,685,673: Method and system for measuring C-reactive protein
• U.S. Trademark No. 877,829: CardioPhase hsCRP